Excited to wrap up day one at ISPOR Europe in Glasgow, Scotland.
Come check out my session with Tiago Beck on Tuesdays from 11:30-12:00 pm.
The EU pharmaceutical package: where are we and where are we going?
speakers
Tiago Beck, MSc, FTI Consulting, Brussels, Belgium; Jason Shafrin, PhD, FTI Consulting, Los Angeles, CA, United States
As trilateral negotiations on the EU pharmaceutical package progress, stakeholders across the healthcare ecosystem are watching closely. This amendment aims to reshape incentives, regulatory pathways and access mechanisms across Europe – with direct impacts on payers, HTA bodies, industry and patients. In this quick facts session, we’ll explain where the legislative process currently stands and what the key issues will shape the final agreement. Areas of focus include: 1) progress and timelines in the triad phase; 2) potential impact on data and market security; 3) Revised incentives for orphan and pediatric drugs; 4) interaction with the EU’s industrial and competitiveness objectives; and 5) potential implications for national level pricing, reimbursement, and access. With important decisions ahead, this session provides a brief policy snapshot to understand where the EU pharma package is headed and why it is important for health economists and payers alike.
